Activity Title: A Practical Overview of The Evolving Landscape of Atopic Dermatitis Management
Release Date: April 30, 2019
Expiration Date: April 30, 2020
Estimated time to complete activity: 1.25 hours
1.25 hour activity | ACCME, ACPE
1.2 hour activity | ANCC
Target Audience:
This activity has been designed to meet the educational needs of Dermatologists, physician assistants, pharmacists, nurses/nurse practitioners and other health care practitioners involved in the care of patients with Atopic Dermatitis.
Learning Objectives:
Upon completion of the educational activity, participants should be able to:
- Identify AD based on the evaluation of clinical characteristics specific to infants, children, adolescents, and adult patients
- List approaches for the assessment of AD severity in order to optimize treatment based on the current guidelines and recommendations
- Review the efficacy and safety of current and emerging treatments for AD patients
- Develop individualized treatment plans for patients with moderate-to-severe AD based on the efficacy and safety of current and new agents, treatment recommendations, and patient preferences
Commercial Support
This activity is supported by an independent medical education grant from LEO Pharma
Provided By
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and South Beach Symposium in collaboration with Postgraduate Institute for Medicine
Faculty
Leon Kircik, MD, Chairperson
- Clinical Associate Professor
- Icahn School of Medicine at Mount Sinai, NY
- Indiana Medical Center, Indianapolis, IN
- Medical Director
- Physicians Skin Care, PLLC, Louisville, KY
- DermResearch, PLLC, Louisville, KY
Giuseppe Micali, MD, Faculty
- Professor of Dermatology at the University of Catania
Lawrence Schachner, MD, Chairperson
- President of the American Society for Pediatric Dermatology
- Professor of the Department of Dermatology, Professor of Pediatrics and Co-Director of the Division of Pediatric Dermatology at the University of Miami Miller School of Medicine
- Miami, FL
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and South Beach Symposium. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy Continuing Education
Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
This program is assigned ACPE Universal Activity #0797-9999-19-051-H01-P. This program is designated for up to 1.25 contact hours (.125 CEUs) of continuing pharmacy education credit.
Type of Activity
Knowledge
Nursing Continuing Education
Accreditation Statement
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation
1.2 contact hours may be earned for successful completion of this activity. Designated for 0.3 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
A statement of credit will be issued only upon successfully completing the post-test with a score of 75% or better and the activity evaluation.
Fee Information
There is no fee for this educational activity.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
FACULTY DISCLOSURE |
NAME |
RELATIONSHIP |
COMPANY |
Leon Kircik, MD |
Advisory Board |
Aclaris, Allergan, Inc., Almirall, Anacor Pharmaceuticals, Biogen-Idec, Colbar, Celgene, Cipher, Connetics Corporation, EOS, Exeltis, Ferndale, Laboratories, Inc., Foamix, Genentech, Inc., Intendis, Innocutis, Isdin, Johnson & Johnson, Nano Bio, OrthoNeutogena, Promius, Quinnova, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma,, Valeant Pharmaceuticals Intl, Warner-Chilcott |
Consultant |
Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Colbar, Cipher, CollaGenex, Connetics Corporation, Exeltis, Foamix, Genentech, Inc., Intendis, Isdin, Johnson & Johnson, Laboratory Skin Care Inc, LEO, Medical International Technologies, Merck, Merz, Novartis AG, OrthoNeutrogena, Promius, PuraCap, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, UCB, Valeant Pharmaceuticals, ZAGE |
Contracted Research |
Acambis, Allergan, Inc., Amgen, Inc., Anacor Pharmaceuticals, Astellas Pharma US, Inc., Asubio, Berlex Laboratories (Bayer HealthCare Pharmaceuticals),Biolive, Biopelle, Boehringer-Ingleheim, Breckinridge Pharma, Celgene, Centocor, Inc. Cellceutix, Coherus, CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermavant, Dermira, Dow Pharmaceutical Sciences, Inc.,, DUSA, Eli Lilly, Exeltis, Ferndale Laboratories, Inc., Foamix, Genentech, Inc., GlaxoSmithKline, PLC, Healthpoint, LTD, Idera, Intendis, Innocutis, Johnson & Johnson, LEO, L’Oreal, 3MMaruho, Medicis Pharmaceutical Corp., Merck, Nano Bio, Novartis AG, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, Promius, QLT, Inc.Quinnova, Quatrix, PharmaDerm, Pfizer, SkinMedica, Inc., Stiefal Laboratories, Inc., Sun Pharma, TolerRX, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort |
Speakers Bureau |
Abbott Laboratories, Allergan, Inc., Amgen, Inc., Assos Pharma, Astellas Pharma US, Inc., Cipher, CollaGenex, Connectics Corporation, Dermik Laboratories, Embil Pharmaceuticals ,Exeltis, Foamix, Genentech, Inc., Innocutix, Innoval, Johnson & Johnson, LEO, L’Oreal, 3M, Onset, OrthoNeutrogena, PediaPharma, PharmaDerm, Serono (Merck Serono International SA),SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, Triax, UCB, Valeant Pharmaceuticals, Intl, Warner-Chilcott, |
Stock |
Johnson & Johnson |
Giuseppe Micali, MD |
N/A |
Nothing to disclose |
Lawrence Schachner, MD |
Consultant |
Beiersdorf, Cutanea, Hoth, Lexington, Mustela, TopMD |
Contracted Research |
Astellas, Berg Pharma, Ferndale Labs, Lilly, Medimetrics, Novartis, Organogenesis Inc., Pfizer, Stiefel Laboratories |
|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The PIM planners and managers have nothing to disclose.
Charles E. Willis, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
South Beach Symposium planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 30, 2019 through April 30, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.southbeachsymposium.org. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Required hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.
